A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

The US Food and Drug Administration (FDA) has granted orphan drug designation to Poolbeg’s preventative therapy for cancer ...

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results ...

The US-based biotech company has submitted an application to the Saudi Food and Drug Authority (SFDA) for Breakthrough Medicine Designation, a fast-track regulatory pathway that could make Multikine ...

Biopharmaceutical company Poolbeg Pharma said the US Food and Drug Administration has granted Orphan Drug Designation (ODD) ...

A novel machine learning model enhances colorectal cancer (CRC) prognosis and immunotherapy response prediction by ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

POLB 001 has been granted FDA orphan drug designation as a preventative therapy for cytokine release syndrome caused by ...

RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical ...

University of Michigan researchers have identified herpes virus saimiri, which infects the T cells of squirrel monkeys, as a ...